Clinically Relevant Drug Interactions in the Treatment of Second-Generation Antipsychotics

1.    Mosolov S.N. Osnovy psikhofarmakoterapii. – M: Vostok, 1996. – 288 s. 
2.    Neznanov N.G., Mosolov S.N., Ivanov M.V. Psikhofarmakoterapiya // Psikhiatriya: natsional'noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. – M.: GEOTAR-Media, 2018. – S. 820–893.
3.    Psikhiatriya: spravochnik prakticheskogo vracha / pod red. A.G. Gofmana. Izd. 2. – M.: MEDpress-inform, 2010. – 592 s. 
4.    Mosolov S.N., Kapiletti S.G., Tsukarzi E.E. Antipsikhoticheskaya farmakoterapiya shizofrenii: ot nauchnykh dannykh k klinicheskim rekomendatsiyam // Biologicheskie metody terapii psikhicheskikh rasstroistv. Dokazatel'naya meditsina – klinicheskoi praktike / pod red. S.N. Mosolova. – M.: Sotsial'no-politicheskaya mysl', 2012. – S. 11–60. 
5.    Mosolov S.N., Kalinin V.V., Eremin A.V. Sravnitel'naya effektivnost' i perenosimost' novogo pokoleniya antipsikhoticheskikh sredstv pri lechenii obostrenii shizofrenii (metaanaliz original'nykh issledovanii olanzapina, risperidona, kvetiapina, klozapina i galoperidola) // Novye dostizheniya v terapii psikhicheskikh zabolevanii. – M.: BINOM. Laboratoriya znanii, 2002. – S. 82–94.
6.     Spina E., Scordo M., D’Arrigo C. Metabolic drug interaction with new psychotropic agents // Blackwell Publishing Fundamental and Clinical Pharmacology. – 2003. – Vol. 17. – P. 517–538. 
7.    Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina, Yu.B. Belousova, V.V. Yasnetsova.  8-e izd., pererab. i dop.  M.: Ekho, 2007 (M.: Shcherbinskaya tipografiya).  1003 s.
8.    Kostyuk G.P., Shmukler A.B., Golubev S.A. i dr. Epidemiologicheskie aspekty diagnostiki shizofrenii v Moskve // Sotsial'naya i klinicheskaya psikhiatriya. – 2017. – № 3. – S. 5–9.
9.    Brett A., Dortch M., Ereshefsky L. et all. S.Clinically Significant Psychotropic Drug-Drug Interactions in the Primary Care Setting // Curr Psychiatry Rep. – 2012. – Vol. 14. – P. 376–390. 
10.    Baltkais Ya.Ya., Fateev V.A. Vzaimodeistvie lekarstvennykh sredstv. – M.: Meditsina, 1991. – 304 s. 
11.    Syunyakov T.S. Vzaimodeistviya lekarstvennykh sredstv pri antipsikhoticheskoi terapii shizofrenii: pravil'nye i riskovannye sochetaniya lekarstvennykh sredstv // Sovremennaya terapiya psikhicheskikh rasstroistv. – 2013. – № 1. – S. 11–17.
12.    Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A. G. Chuchalina, V.V. Yasnetsova. – Vyp. XIII. – M.: Ekho, 2012. – 984 s.
13.    Spina E., Hiemke C., De Leon J. Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics // Expert Opin Drug MetabToxicol. – 2016. – Vol. 12 (4). – P. 407–422. 
14.    Fleeman N., Dundar Y., Dickson R. et al. Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses // Pharmacogenomics J. – 2011. – Vol. 11. – P. 1–14. 
15.    Arranz M.J., Rivera M., Munro J.C. Pharmacogenetics of response to antipsychotics in patients with schizophrenia // CNS Drugs. – 2011. – Vol. 25. – P. 933–969. 
16.     Kapitany T., Meszaros K., Lenzinger E. et al. Genetic polymorphisms for drug metabolism (cyp2d6) and tardive dyskinesia in schizophrenia // Schizophr Res. – 1998. – Vol. 32. – P. 101–106. 
17.    Malin D.I. Pobochnoe deistvie psikhotropnykh sredstv. – M: Vuzovskaya kniga, 2000. – 207 s. 
18.    Spivak L.I., Raiskii V.A., Vilenskii B.S. Oslozhneniya psikhofarmakoterapii. – L.: Meditsina, 1988. – 168 s.
19.    Federal'noe rukovodstvo po ispol'zovaniyu lekarstvennykh sredstv (formulyarnaya sistema) / pod red. A.G. Chuchalina, Yu.B. Belousova, V.V. Yasnetsova. – Izd. 7-e, pererab. i dop. – M.: Ekho, 2006. 
20.    Naber D., Leppig M., Grohmann R., Hippius H. Efficacy and adverse effects of clozapine in the treatment of schizophrenia and tardive dyskinesia-a retrospective study of 387 patients // Psychopharmacology (Berl). – 1989. – Vol. 99. ( Suppl.). – P. 73–76.
21.    Mosolov S.N., Tsukarzi E.E. Psikhofarmakoterapiya shizofrenii // Psikhiatriya: Natsional'noe rukovodstvo / pod red. N.G. Neznanova, Yu.A. Aleksandrovskogo. – M.: GEOTAR-Media, 2018. – S. 578–633.
22.    Song S. Cardiotoxicity of antipsychoticdrugs: Abnormal ECG in 1266 cases // Chung Hua Shen Ching Shen Ko Tsa Chih. – 1989. – Vol. 22 (2). – P. 77–79. 
23.    Warner J., Barnes T., Henry J. Electrocardiographic changes in patients receiving neuroleptic medication // Acta Psychiatr Scand. – 1996. – Vol. 93 (4). – P. 311–313. 
24.    Glassman A, Bigger J. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death // Am J Psychiat. – 2001. – Vol. 158. – P. 1774–1782.
25.    Volkov V.P. Kardiotoksichnost' fenotiazinovykh neiroleptikov (obzor literatury) // Psikhiatriya i psikhofarmakoterapiya. – 2010. – № 2. – S. 41–45.
26.    Aunsholt N.A. Prolonged Q-T interval and Hypokalemia by haloperidol // Acta Psychiatr Scand. – 1989. – Vol. 79 (4). – P. 411–420.
27.    Pfizer. Briefing document for ziprasidone HC1 presented at the FDA. – Psychopharmacological Drugs Advisory Committee. – July 19, 2000.
28.    Gottschalk E., Dinovo E., Biener R., Nandi B. Plasma concentrations of thioridazine metabolites and ECG abnormalities // J Pharm Sci. – 1978. – Vol. 67 (2). – P. 155–157.
29.    Metzger E., Friedman R. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill // J Clin Psychopharmacol. – 1993. – Vol. 13 (2). – P. 128–132.
30.    Nielsen J., Wang F., Graff C., Kanters J. QT dynamics during treatment with sertindole // Ther Adv Psychopharmacol. – 2015. – Vol. 5 (1). – P. 26–31.
31.    Hiroyoshi T.,TakefumiS.,Gary R. and Hiroyuki U. Antipsychotic polypharmacy and corrected QT interval: A systematic review // Can J Psychiatry. – 2015. – Vol. 60 (5). – P. 215–220.
32.    Reilly J.G., Ayis S.A., Ferrier IN. et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients // Lancet. – 2000. – Vol. 355. – P. 1048–1052. 
33.    Rosenzweig P., Canal M., Patat A. et al. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers // Human Psychopharmacology. – 2002. – Vol. 17, No. 1. – P. 1–13. 
34.    Daniel D.G., Saha A.R. Inenito G. et al. Aripiprazole, a novel antipsychotic: overview of a phase II study result // Int J Neuropsyhopharmacol. – 2000. – Vol. 3 (Suppl. 1). – P. 157–174.
35.    Liverpool Drug Interaction Group // Interactions with Experimental COVID-19 Therapies. – April, 9, 2020.
36.    Aung C.L., Brien J.C., Nien P.C et al. Increased aripiprazole concentration in an HIV - positive male concurrently taking duloxetine, darunavir and ritonavir // Ann Pharmacoter. – 2010. – Vol. 44 (11). – P. 1850–1854.
37.    Goodlet K.J., Zmarlicka M.T. and Peckham A.M. Drug-drug interaction and clinical considerations with co-administration of antiretrovirals and psychotropic drugs // CNS Spectrums. – 2018. – P. 1–26. 
38.    Leon J., Spina E. Possible Pharmacodynamic and Pharmacokinetic Drug-Drug Interactions That Are Likely to Be Clinically Relevant and/or Frequent in Bipolar Disorder // Current Psychiatry Reports. – 2018. – Vol. 20. – P. 17. 
39.    Prakash C., Kamel A., Cui D. et al.Identification of the major human liver cytochromeP450 isoform(s) responsible for the formation of theprimary metabolites of ziprasidone and prediction of possible drug interactions // Br J Clin Pharmacol. – 2000. – Vol. 49 (Suppl. 1). – P. 35–42.
40.    Miceli J.J., Anziano R.J., Robarge L. et al.The effect of carbamazepine on the steady-state pharmacokinetics of ziprasidone in healthy volunteers // British Journal of Clinical Pharmacology. – 2000. – Vol. 49 (Suppl. 1). – P. 65–70. 
41.    Miceli J.J., Smith M., Robarge L. et al. The effects of ketoconazole on ziprasidone pharmacokinetics—a placebo-controlled crossover study in healthy volunteers // British Journal of Clinical Pharmacology. – 2000. – Vol. 49 (Suppl. 1). – P. 71–76. 
42.    Komossa K., Rummel-Kluge C., Hunger H. et al. Ziprasidone versus other atypical antipsychotics for schizophrenia // Cochrane Database Syst Rev. – 2009. – Vol. 7 (4). – P. 81–90.
43.    Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability // Expert Opinion on Drug Metabolism & Toxicology. – 2013. – Vol. 9, No. 2. – P. 193–206.
44.    Bazire S. Drug interaction // Psychotropic Drug Directory (The Professionals Pocket Handbook and Aide Memoire). – Quay Books Division. – 2002. – P. 223–230.
45.    Shen W.W. The metabolism of atypical antipsychotic drugs: an update // Ann Clin Psychiatry. – 1999. – Vol. 1. – P. 145–158. 
46.    Dev V., Raniwalla J. Quetiapine: a review of its safety in the management of schizophrenia // Drug Saf. – 2000. – Vol. 23. – P. 295–307.
47.    Wong Y.W.J., Yeh C., Thyrum P.T. The effects of concomitant phenytoin administration on the steady-state pharmacokinetics of quetiapine // J Clin Psychopharmacol. – 2001. – P. 2189–2193. 
48.    Eierman B., Engel G., Johansson I. et al. The involvement of CYP1A2 and CYP3A4 in the metabolismof clozapine // Br J Clin Pharmacol. – 1997. – Vol. 44. – P. 439–446. 
49.    Linnet K., Olesen O.V. Metabolism of clozapine by c DNA expressed human cytochrome P450 enzymes // Drug Metab Dispos. – 1997. – Vol. 25. – P. 1379–1382. 
50.    Taylor D. Pharmacokinetic interactions involving clozapine // Br J Psychiatry. – 1997. – Vol. 17. – P. 109–112. 
51.     Edge S.C., Markowitz J.S., DeVane C.L. Clozapine drug interactions: a review of the literature// Hum. Psychopharmacol.-1997.-Vol. 12. - P. 5–20. 
52.     Facciola` G., Avenoso A., Scordo G.M. et al. Small effects of valproic acid on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenic or affective disorders // Ther Drug Monit. – 1999. – Vol. 21. – P. 341–345. 
53.     Longo L.P., Salzman C. Valproic acid effects on serum concentrations of clozapine and norclozapine // Am J Psychiatry. – 1995. – Vol. 152. – P. 650–654. 
54.     Iqbal M.M., Rahman A., Husain Z. et al. Clozapine: a clinical review of adverse effects and management // Ann Clin Psychiatry. – 2003. – Vol. 15. – P. 33–48.
55.     Lieberman J.A. Maximizing clozapine therapy: managing side effects // J Clin Psychiatry. – 1998. – Vol. 59 (Suppl. 3). – P. 38–43. 
56.     Blake L.M., Marks R.C., Luchins D.J. Reversible neurologic symptoms with clozapine and lithium // J Clin Psychopharmacol. – 1992. – Vol. 12 (4). – P. 297–299. 
57.     Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic // Clin Schizophr Relat Psychoses. – 2011. – Vol. 4, No. 4. – P. 251–257. 
58.    Greenberg W.M., Citrome L. Pharmacokinetics and pharmacodynamics of Lurasidone Hydrochloride, a Second-generation antipsychotic: A systematic review of the published literatur // Clin Pharmacokinet. –2017. – Vol. 56 (5). – P. 493–503. 
59.    Kassahun K., Mattiuz E., Nyhart E. et al. Disposition and biotransformation of the antipsychotic agent olanzapine inhumans // Drug Metab Dispos. – 1997. – Vol. 25. – P. 81–93. 
60.    De Jong J., Hoogenboom B., van Troostwijck L.D., De Hann L. Interaction of olanzapine with fluvoxamine // Psychopharmacology. – 2001. – Vol. 156. – P. 219–220. 
61.    Hiemke C., Avi P., Jabarin M. et al. Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects // J Clin Psychopharmacol. – 2002. – Vol. 22. – P. 502–506. 
62.    Markowitz J.S., DeVane C.L. Suspected ciprofloxacin inhibition of olanzapine resulting in increased plasma concentrations // J Clin Psychopharmacol. – 1999. – Vol. 19. – P. 289–291. 
63.     Gossen D., de Suray J.M., Vandenhende F., Onkelinx C., Gangji D. Influence of fluoxetine on olanzapine pharmacokinetics // AAPS Pharm Sci. – 2002. – Vol. 4. – P. 11–16. 
64.    Callaghan J.T., Bergstrom R.F., Ptak L.R., Beasley C.M. Olanzapine: Pharmacokinetic and pharmacodynamic profile // Clin Pharmacokinet. – 1999. – Vol. 37. – P. 177–193. 
65.     Lucas R.A., Gilfillan D.J., Bergstrom R.F. A pharmacokinetic interaction between carbamazepine and olanzapine: observationson possible mechanisms // Eur J Clin Pharmacol. – 1998. – Vol. 54. – P. 639–643. 
66.     Olesen O.V., Linnet K. Olanzapine serum concentrations in psychiatric patients given standard doses: the influence of comedication // Ther Drug Monit. – 1999. – Vol. 21. – P. 87–90. 
67.     Penzak S.R., Hon Y.Y., Lawhorn W.D. et al. Influence of ritonavir on olanzapine pharmacokinetics in healthy volunteers // J Clin Psychopharmacol. – 2002. – Vol. 22. – P. 366–370. 
68.    Citrome L. Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability // Expert Opinion on Drug Metabolism and Toxicology. – 2012. – Vol. 8. – P. 873–888. 
69.    Fang J., Bourin M., Baker G.B. Metabolism of risperidone to 9-hydroxyrisperidone by human cytochrome P450 2D6 and3A4 // Naunyn Schmiederbergs Arch. Pharmacol. -1999.-Vol. 359.-P.147–151. 
70.     Yasui-Furukori N., Hidestrand M., Spina E. et al. Different nantioselective 9-hydroxylation of risperidone by the two human CYP2D6 and CYP3A4 enzymes // Drug Metab Dispos. – 2001. – Vol. 29. – P. 1263–1268. 
71.     Huang M.L., Van Peer A., Woestenborghs R. et al. Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactin response in healthy subjects // Clin Pharmacol Ther. – 1993. – Vol. 54. – P. 257–268. 
72.     Scordo M.G., Spina E., Facciola` G. at al. Cytochrome P450 2D6 genotype and steady-stateplasma levels of risperidone and 9-hydroxyrisperidone // Psychopharmacology. – 1999. – Vol. 147. – P. 300–305. 
73.     DeVane C.L., Nemeroff C.B. An evaluation of risperidone drug interactions // J Clin Psychopharmacol. – 2001. – Vol. 21. – P. 408–416. 
74.     Bondolfi G., Eap C.B., Bertschy G. et al. The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychiatric patients // Pharmacopsychiatry. – 2002. – Vol. 35. – P. 50–56. 
75.     Spina E., Avenoso A., Facciola` G, et al. Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine // Ther Drug Monit. – 2001. – Vol. 23. – P. 223–227. 
76.     Spina E., Avenoso A., Scordo M.G. et al. Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction // J Clin Psychopharmacol. – 2002. – Vol. 22. – P. 419–423. 
77.    Amchin J., Zarycransky W., Taylor K.P. et al. Effect of venlafaxine on the pharmacokinetics of risperidone // J Clin Pharmacol. – 1999. – Vol. 39. – P. 297–309. 
78.     Sommers D.K., Snyman J.R., van Wyk M. et al. Lack of effect of amitriptyline on risperidone pharmacokinetics in schizophrenic patients // Int Clin Psychopharmacol. – 1997. – Vol. 12. – P. 141–143.
79.     De Leon J., Bork J. Risperidone and cytochrome P450 3A // J Clin Psychiatry. – 1997. – Vol. 58. – P. 450. 
80.     Spina E., Scordo M.G., Avenoso A, Perucca E. Adverse drug interaction between risperidone and carbamazepine in a patient with chronic schizophrenia and deficient CYP2D6 activity // J Clin Psychopharmacol. – 2001. – Vol. 21. – P. 108–109. 
81.     Spina E., Zoccali R. Sertindole: pharmacologicaland clinical profile and role in the treatment of schizophrenia // Expert Opin Drug MetabToxico. – 2008. – Vol. 4. – P. 629–638. 
82.     Lindstrom E., Farde L., Eberhard L., Haverkamp W. QTc interval prolongation and antipsychotic drug treatments: focus on sertindole // Int J Neuropsychopharmacol. – 2005. – Vol. 8. – P. 615–629.